Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL   4:00:00 PM EDT
15.76
+0.57 (+3.75%)
6:32:35 PM EDT: $17.20 +1.44 (+9.14%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.12B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$15 Million
Adjusted EPS-$0.77
See more estimates
10-Day MA$14.48
50-Day MA$13.46
200-Day MA$18.60
See more pivots

Zentalis Pharmaceuticals Inc Stock, NASDAQ:ZNTL

1359 Broadway, Suite 801, New York, New York 10018
United States of America
Phone: +1.212.433.3791
Number of Employees: 168

Description

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.